Avrobio Planning Pivotal Trial of AVR-RD-01 Gene Therapy for Fabry

Avrobio Planning Pivotal Trial of AVR-RD-01 Gene Therapy for Fabry

294280

Avrobio Planning Pivotal Trial of AVR-RD-01 Gene Therapy for Fabry

Avrobio is in the planning stages of a clinical trial to support a request for approval of AVR-RD-01 as a first-line gene therapy for people with  Fabry disease. This registration trial, which the company hopes to initiate in mid-2022 with U.S. Food and Drug Administration (FDA) agreement, will test the gene therapy head-to-head against Sanofi Genzyme’s Fabrazyme (agalsidase beta), Avrobio reported in a press release. “We look forward to working with FDA and other regulators to design a single…

You must be logged in to read/download the full post.